MX2022013400A - Composicion que comprende un anticuerpo ige. - Google Patents

Composicion que comprende un anticuerpo ige.

Info

Publication number
MX2022013400A
MX2022013400A MX2022013400A MX2022013400A MX2022013400A MX 2022013400 A MX2022013400 A MX 2022013400A MX 2022013400 A MX2022013400 A MX 2022013400A MX 2022013400 A MX2022013400 A MX 2022013400A MX 2022013400 A MX2022013400 A MX 2022013400A
Authority
MX
Mexico
Prior art keywords
composition
ige antibody
ige
antibody
unit dosage
Prior art date
Application number
MX2022013400A
Other languages
English (en)
Inventor
Mariangela Figini
James Spicer
Sophia Karagiannis
Hannah Gould
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006093.5A external-priority patent/GB202006093D0/en
Application filed by King S College London filed Critical King S College London
Publication of MX2022013400A publication Critical patent/MX2022013400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En un aspecto, la presente invención se refiere a una composición farmacéutica de dosificación unitaria que comprende un anticuerpo del isotipo inmunoglobulina E (IgE), en donde la composición comprende menos de 50 mg del anticuerpo IgE.
MX2022013400A 2020-04-24 2021-04-23 Composicion que comprende un anticuerpo ige. MX2022013400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006093.5A GB202006093D0 (en) 2020-04-24 2020-04-24 Composition
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody

Publications (1)

Publication Number Publication Date
MX2022013400A true MX2022013400A (es) 2023-01-04

Family

ID=84195343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013400A MX2022013400A (es) 2020-04-24 2021-04-23 Composicion que comprende un anticuerpo ige.

Country Status (9)

Country Link
US (1) US12606617B2 (es)
EP (1) EP4139356A1 (es)
JP (1) JP2023523264A (es)
KR (1) KR20230006824A (es)
CN (1) CN115916829A (es)
AU (1) AU2021260852A1 (es)
BR (1) BR112022021499A2 (es)
CA (1) CA3176300A1 (es)
MX (1) MX2022013400A (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2848842C (en) 2011-10-04 2020-09-29 King's College London Ige anti -hmw-maa antibody
US9587032B2 (en) * 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物

Also Published As

Publication number Publication date
JP2023523264A (ja) 2023-06-02
KR20230006824A (ko) 2023-01-11
CA3176300A1 (en) 2021-10-28
CN115916829A (zh) 2023-04-04
AU2021260852A1 (en) 2022-12-01
BR112022021499A2 (pt) 2023-05-09
US20230151090A1 (en) 2023-05-18
EP4139356A1 (en) 2023-03-01
US12606617B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
MX2025010757A (es) Formulacion farmaceutica de ph bajo
CL2019001740A1 (es) Novedoso conjugado de amanitina.
MX2020007697A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos.
MX2020006957A (es) Composicion de liberacion modificada que comprende un cannabinoide.
BR112022018949A2 (pt) Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
EA201792451A1 (ru) Антитела к ox40 и способы их применения
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
MX2019004955A (es) Compuestos del peptido tirosina tirosina ciclico con anticuerpo acoplado como moduladores de receptores de neuropeptido y receptores.
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
BR112021025161A2 (pt) Anticorpo anti-epha4
MX2022001133A (es) Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
JOP20230109A1 (ar) أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات
PE20211296A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
JOP20220057A1 (ar) علاج أمراض أو اضطرابات الكبد تشتمل على مضادات مستقبل actrii
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)